TERMS AND CONDITIONS
GHAGA awards Terms and Conditions
These terms and conditions (the "T&Cs") are intended to govern the operation of the Grifols Hemophilia Awareness Global Awards (the "GHAGA Awards") organized by Grifols, S.A., a company duly incorporated under the laws of Spain, with Tax ID number A-58389123, and with registered offices at calle Jesús y María 6, 08022 Barcelona – Spain ("Grifols").
GHAGA Awards aim at improving the standards and benefits for the patient care in hemophilia where it is not yet or not easily available.
These T&Cs are available for consultation on www.grifols.com (the "Website").
Participation in the GHAGA Awards is voluntary and free of charge. Participants may be healthcare professionals, medical and paramedical centers, as well as hemophilic societies that contribute to improve the quality of life of hemophilia patients.
The participants in the GHAGA Awards may present their proposal individually or as part of a research team. Both individual participants and research team participants will be jointly referred to as the "Participants".
The Participants shall meet the following eligibility requirements:
- submit an innovative proposal that (i) fulfills the project objectives set forth in Section 4.1 below, and (ii) constitutes a focused project with goals that can be achieved within a term of twelve (12) to eighteen (18) months;
- be a healthcare organization, such as hospitals, universities, or independent institutions ("HCO") or a healthcare professional (including without limitation doctors, nurses, scientists, pharmacists, or physical therapists) ("HCP");
- develop a project in the field of hemophilia;
- Participants who are an HCP must be employed and/or explicitly supported by a HCO, and
- be resident or incorporated in a country member of the United Nations and in which the Project is intended to be carried out.
None of Grifols' and/or its group companies' personnel or any relative up to the second degree of kinship of the persons directly involved in the management of the GHAGA Awards or in the awardee selection process shall be eligible to participate in the GHAGA Awards.
In no case and under no circumstance shall Grifols bear any costs and/or expenses (such as, bank charges and/or any applicable taxes) in which the Participants may incur by reason of their participation in the GHAGA Awards and the granting of the Prize (as such term is defined below).
3. Period of participation and timeline
The period of participation for the GHAGA Awards will start on 17th June 2020 and finish on 30th November 2020 and shall include the following phases or steps:
(a) Submission of the application form of the Proposal (as such term is defined below) following the template provided by Grifols, which shall include a dossier with the following information (the "Dossier"):
(i) A brief résumé or CV (of only one Participant)
(ii) Letter of Intent, accessible on the Website, containing:
- A brief description of the HCO either as applicant, or as an employer and supporter of the Participants who are HCPs
- Description of the Project (background, objectives, design, and contribution to quality of life improvement)
- Timelines and budget
- Brief biography of the Participant
(iii) A letter of authorization from the HCO expressly authorizing the HCP to submit a Proposal in relation with a Project. The letter must be stamped and signed by the Director (or equivalent position) of the HCO. There is a template of such letter of authorization on the website available for download.
(b) The Dossier shall be submitted to Grifols no later than 30th November 2020.
(c) Upon receipt of the Dossiers, the Review Committee (as such term is defined in Section 4 below) shall select the Participants admitted to submit a full Proposal. The full Proposal shall be submitted no later than 15th March 2021. Such Participants will receive additional questions and/or an additional questionnaire from Grifols to be completed;
(d) Submission by the Participants of additional questionnaires and/or questions, as requested by Grifols under paragraph (b) above;
(e) Selection by the Review Committee of the full Proposals awarded in each of the four categories defined in Section 4.1 (a); and
(f) Announcement by Grifols of the GHAGA Awards to each of the Awardees and announcement on the website on 30th April 2021.
(g) The Awards ceremony will be held, when possible, during an international health congress or in an event organized by Grifols (the "Awards Ceremony"), which will be notified to the Awardees in advance.
The Participants shall provide all information requested in the course of the selection process in ENGLISH using the form or documents provided by Grifols, when they are made available.
PLEASE KINDLY NOTE: Only complete Dossiers will be further assessed in the selection process for the GHAGA Awards. At each step, the Proposals of the Participants, which Dossiers do not meet the eligibility or other requirements, will be disqualified and will not be considered for the rest of the Awardees selection process.
4. Award details
Applicants (either individual Participants or Participants part of a research team designated by a HCO to submit the proposal (the "Proposal")) have to complete a Dossier and submit it following the terms set forth in Section 3.
Once the period to submit the Dossier ends, an independent jury formed by a panel of leading experts in clinical and academic medicine, whose identity details are published on the Website (the "Review Committee"), shall select:
(a) In a first step, among the Participants having submitted a Dossier, the Participants admitted to submit a full Proposal. Since Grifols is fully committed to adhering to the highest integrity and ethical standards, and expects the same of any person with whom interactions are established, Grifols will request the Participants admitted to submit a full Proposal, to complete an additional questionnaire, as a condition for further consideration of their Proposal in the Awardees' selection process;
(b) In a second step, among the Participants having submitted a full Proposal, the five (5) Participants' Projects (as such term is defined below) that best match the objectives of the Project (as detailed in Section 4.1), taking into consideration the appraisal criteria described in Section 4.2 (the "Awardees").
Only Participants fulfilling all of the above requirements and criteria will be considered to be selected as Awardees. The Awardees will be required to enter into a contract with the HCO and Grifols before the award of the Prize (as such term is defined below) (the "Contract"), which shall set forth the terms and conditions by which the Prize will be granted to the HCOs employing or supporting the Awardees.
The Awardees will be announced on the Website with their name, last name, title, designation of work place, and the title of the Project.
The Awardees are required to attend the Awards Ceremony, when possible, in order to receive the Prize. Any costs and/or expenses associated with attendance of the Awardees to the Awards Ceremony will be borne by Grifols or, if these have been already paid by the Awardees or the Awardees' HCO, the Awardees or the Awardees' HCO shall be reimbursed by Grifols upon Grifols being provided with evidence of the costs and/or expenses incurred and subject, in any event, to any applicable local laws and regulations.
4.1 Requirements of the Projects
Participants shall present an innovative project that contributes to improve the quality of life of hemophilia patients and that permits complying with the following requirements (the "Project"):
(a) Project objectives
(i) Outreach diagnosis by increasing disease awareness or access to diagnosis (endorse reference centers to work on better logistics or facilities, support national or local registries, help to develop hemophilia treatment centers' processes);
(ii) Improve education to patients, families, caregivers, healthcare providers, or patient's advocacy groups (educational stages in other centers, workshops, pathology training, and programs to educate patients and families);
(iii) Strengthen diagnosis (help to improve patients' care and quality control in hemophilia centers); and/or
(iv) Facilitate access to treatment (support patient or family travels, improve in logistics organization).
(b) Project goals should be achieved within a term of twelve (12) to eighteen (18) months from the date of the first payment agreed in the Contract, in case Participants become selected as Awardees.
(c) In no case, submitted Projects shall include any information or data which allows, directly or indirectly, the identification of any individual who is not a member of the Participant's team and/or the HCO.
(d) The Project funding request will be submitted in local currency as well as the breakdown costs requested in the full Proposal. The funds approved by the Review Committee will not be modified under any circumstances.
In case a Participant becomes selected as Awardee, he/she agrees to provide Grifols with progress reports (which shall include a financial report of the fund and any other Project realization evidence) within the term specified in each Contract (which will differ based on the characteristics of each Project) and a full report after completion of the Project (the "Final Report"). Eventually, details of the Projects awarded (description and execution) will be used and published by Grifols in reports, newsletters, and media releases related to the GHAGA Awards news, in accordance with the terms and conditions set forth in the corresponding Contract.
4.2 Appraisal criteria
The Projects will be assessed by the Review Committee taking into account the following criteria:
(a) Scientific merit, which will take into account (i) the validity of the expected outcomes, (ii) the validity of its potential regional impact, and (iii) the feasibility of completing the proposed work within a term of twelve (12) to eighteen (18) months from the date of the first payment agreed in the Contract;
(b) Clinical/medical impact, which will take into account (i) the validity of the rationale/expected outcomes to contribute to increase disease awareness and/or access to diagnosis, offer education or improve patient care, and (ii) proposals showing potential regional impact (which will be highly evaluated); and
(c) Plan execution and grant Awardees, which will take into account (i) qualification of each Participant and of the HCO supporting the Participant, (ii) expertise in the area where the Proposal will be executed, and (iii) profile of the Participant.
Each of the five (5) selected Projects will be awarded with a maximum amount of Euros 30,000 (the "Prize") or the corresponding exchange in USD or local currency. The exchange rate that will be taken into consideration shall be the one published on the issue date of the invoice. The final Prize to be granted within this maximum amount will depend on the specific characteristics of each Project, as each Project shall specify and properly justify the sum of money required for its execution. Payment of the Prize will be made by Grifols to the Awardees.
The Awardee(s) acknowledges that Grifols will not transfer any payment of the Prize of the GHAGA Awards directly to him/her/them.
6. Representations and Warranties. Intellectual and Industrial Property
The Participants represent and warrant that (a) they are the authors responsible for the submitted Project, (b) the Dossier, the Proposal, as well as any submitted documents and/or information provided are accurate and updated, (c) the Project is an original creation, (d) they have obtained all necessary approvals from their HCOs to participate in the GHAGA Awards and their participation do not violate any duty owed to such HCOs or any other third party, (e) the Project complies with all applicable health regulations, and (f) their participation in the GHAGA Awards and the exercise by Grifols of the rights licensed herein does not infringe any legal provisions, agreements, rights, or assets owned by any third party.
The HCO or, as the case may be, the Awardee will be the exclusive owner of the economic rights of intellectual and industrial property over the Project. By participating in the GHAGA Awards, Grifols is granted a worldwide, non-exclusive, non-transferable (except to Grifols' group companies), royalty free license to use any and all results derived, directly or indirectly, from the Project for Grifols' internal research and development purposes. The Awardee shall present any information, data, and/or results derived from the Project only with the prior written consent of Grifols, which consent shall not be unreasonably withheld.
7. Data Protection
8. Applicable Law and Jurisdiction
These T&Cs are governed by Spanish law. If any dispute arises from the interpretation and/or execution of the provisions regulated in these T&Cs, the parties will try to resolve these disputes amicably. If the dispute, controversy, or difference cannot be amicably resolved, the parties shall submit the dispute, controversy, or difference exclusively to the courts of the city of Barcelona, Spain.
Participation in the GHAGA Awards implies full and complete acceptance of these T&Cs by each Participant. Any statement to the contrary, such as not agreeing to the T&Cs, will result in the exclusion of the Participant and, as a result, Grifols will be released from fulfilling any obligations with respect to such Participants.
It is hereby acknowledged that none of the Awards granted is conditioned upon any promotion, prescription, and/or use of any products commercialized by Grifols, nor it is intended to influence the Participants (either HCPs or HCOs) to do so.
Grifols reserves the right to (i) cancel the GHAGA Awards at any time on the grounds of force majeure, lack of participation, or for any other valid reason, and (ii) disqualify any Participant who infringes any of the provisions set forth in these T&Cs and/or any applicable regulation.
Further, Grifols reserves the right to modify these T&Cs in case any irregularity is detected that might have an impact on the objectivity and transparency of the GHAGA Awards.
Date of creation: May 2020
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?